CA2802132C — Tetrahydro-pyrido-pyrimidine derivatives
Assigned to Novartis AG · Expires 2019-02-26 · 7y expired
What this patent protects
The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I): Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes. (see above formula)
USPTO Abstract
The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I): Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes. (see above formula)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.